Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease

To establish the relationship between trough vedolizumab levels and outcomes during maintenance therapy. Cross-sectional service evaluation was performed on patients with inflammatory bowel disease (IBD) receiving maintenance vedolizumab therapy (minimum of 12 weeks following induction). Prior to in...

Full description

Saved in:
Bibliographic Details
Published in:Frontline gastroenterology 2020-03, Vol.11 (2), p.117-123
Main Authors: Plevris, Nikolas, Jenkinson, Philip W, Chuah, Cher S, Lyons, Mathew, Merchant, Lynne M, Pattenden, Rebecca J, Arnott, Ian D, Jones, Gareth R, Lees, Charlie W
Format: Article
Language:English
Subjects:
Colorectal
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To establish the relationship between trough vedolizumab levels and outcomes during maintenance therapy. Cross-sectional service evaluation was performed on patients with inflammatory bowel disease (IBD) receiving maintenance vedolizumab therapy (minimum of 12 weeks following induction). Prior to infusion, data on clinical activity (Harvey-Bradshaw Index or partial Mayo score), trough C-reactive protein (CRP)/vedolizumab levels and faecal calprotectin were collected. Endoscopic data (±8 weeks from vedolizumab level testing) were obtained by review of medical records. Vedolizumab levels were processed using the Immundiagnostik monitor ELISA. The Edinburgh IBD Unit, Western General Hospital (tertiary IBD referral centre). Seventy-three patients (30 ulcerative colitis and 43 Crohn's disease) were identified who fulfilled inclusion criteria and had vedolizumab levels matched with clinical activity scores, CRP and faecal calprotectin. Of these, 40 patients also had matched endoscopic data. The association of trough vedolizumab levels with clinical remission (Harvey-Bradshaw Index
ISSN:2041-4137
2041-4145
DOI:10.1136/flgastro-2019-101197